ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1764

B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease

Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Laura Bosello, Angela Carbonella, Silvia Canestri and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies, B cells, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: B cells are involved as central players in the pathogenesis of rheumatoid arthritis (RA). Our aim was to define whether a specific B cell subset characterizes the early phases of the disease and is associated with a peculiar RA phenotype.

Methods: 105 ERA patients (81.0% females; mean age 54.7 ± 15.2 years; 73.3% autoantibodies-AAB positive) and 30 healthy controls (HC) were studied. Baseline clinical and immunological characteristics and inflammatory status were assessed. Peripheral blood samples were analyzed by flow cytometry for the distribution of circulating B cell subsets by staining with surface markers CD19, CD45, CD38, CD27 and IgD and intracellular marker ZAP70. Plasma levels of IL-6 and BAFF were also determined with ELISAs. The expression of ZAP-70 and SYK was analized in B cells of 22 ERA patients, using the RealTime ready Assay method. 

Results: ERA patients showed a higher percentage of naïve-activate B cells and a lower percentage of memory B cells compared to HC, as confirmed by a higher ratio between Bm2+Bm2’/eBm5+Bm5 (3.4±3.5 in ERA and 1.7±0.9 in controls, p=0.003). AAB positive patients showed a higher percentage of CD19+/CD38+CD27+ (4.0±5.0%) compared to AAB negative ones (2.2±2.8%, p=0.05). The expression of ZAP-70 in B cells was similar in ERA patients and controls. Dividing patients for the AAB seropositivity, AAB+ ERA patients showed higher percentage of CD19+/ZAP70+ cells compared to AAB- (5.1±6.3 vs 2.5±2.4, p=0.01) and also to HC (2.2±1.4, p=0.05). In ERA patients, the percentage of ZAP70+ B cells correlated directly with the percentage of CD19+/IgD-CD27- cells (r=0.338, p=0.001), plasma BAFF levels (r=0.26, p=0.01) and with Anti-MCV (r=0.27, p=0.01), ACPA (r=0.23, p=0.02) and RF-IgA (r=0.28, p=0.01) AAB titers. ZAP-70 transcription in B cells of subjects seropositive for autoantibodies was significantly higher than in seronegative ones (3.4 ± 2.8 vs 1.2 ± 1.0 respectively; p=0.04), data confirmed by an higher ratio ZAP70/SYK in AB+ compared to AB- (2.9 ± 1.6 vs 1.2 ± 1.0 respectively; p=0.01). Moreover, the expression of ZAP-70 correlated positively with the expression of SYK (r=0.66, p=0.003) and showed a trend for an association with the espression of ZAP70 protein, evaluated by flow-cytometry (r=0.41, p=0.09). 

Conclusion: ZAP-70 positive B cells characterize AAB positive RA and the expression of ZAP-70 might be a possible complementary biomarker of seropositive disease.


Disclosure:

A. L. Fedele,
None;

B. Tolusso,
None;

E. Gremese,
None;

S. L. Bosello,
None;

A. Carbonella,
None;

S. Canestri,
None;

G. Ferraccioli,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cells-in-early-rheumatoid-arthritis-zap-70-more-than-syk-characterize-seropositive-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology